Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial
Grégoire Stalder,
Madeleine Suffiotti,
Amandine Segot,
Alessandra Noto,
Giuseppe Pantaleo,
Olivier Spertini,
Michel Obeid
Affiliations
Grégoire Stalder
Service and Central Laboratory of Hematology, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne, Switzerland; Service of Hematology and Laboratory of Hematology, Institut Central des Hôpitaux, Hôpital du Valais, Av. du Grand-Champsec 86, CH-1951 Sion, Switzerland; University of Lausanne, Lausanne
Madeleine Suffiotti
Division of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne
Amandine Segot
Service and Central Laboratory of Hematology, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne
Alessandra Noto
Division of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne
Giuseppe Pantaleo
University of Lausanne, Lausanne, Switzerland; Division of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne
Olivier Spertini
Service and Central Laboratory of Hematology, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne, Switzerland; University of Lausanne, Lausanne
Michel Obeid
University of Lausanne, Lausanne, Switzerland; Division of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne
